Introduction to NIFTY™
The NIFTY™ test is a highly accurate non-invasive prenatal test (NIPT) that screens for chromosomal aneuploidies, including trisomies 21, 18 and 13, from as early as week 10 of pregnancy. NIFTY™ provides a significantly stronger risk indication than traditional screening procedures.
With a sensitivity rate of >99% (validated on over 112,000 pregnancies) and a false positive rate of just 0.1% for trisomies 21, 18 and 13, NIFTY™ ensures that the number of women undergoing unnecessary invasive diagnostic procedures is significantly reduced. To date, over 2,000,000 NIFTY samples have been processed worldwide.
Advantages of NIFTY™
- Most validated NIPT on the market with a published study based on the pregnancy outcomes of over 112,000 women.
- The only NIPT on the market to offer testing services for deletion syndromes and sex chromosome aneuploidies at no extra cost.
- Proven low redraw rate of just 2.8% based on over 600,000 tests.
- Largest capacity and coverage making NIFTY™ price competitive against all other NIPT providers.